Group. The in-hospital management strategy against AF for individual patients was decided based on the consensual opinion of 2 experienced cardiologists. Total death and rehospitalization for CHF exacerbation were retrospectively analyzed from hospital discharge until September 2002 (follow-up period of 1-72 months; 34.3±23.3 months).
Clinical Measurement of CHF
Clinical parameters at discharge were analyzed as the patient baseline characteristics for CHF. Venous blood samples for neurohumoral factors were taken from an antecubital vein after 15 min of rest. Plasma B-type natriuretic peptide (BNP) was determined by sensitive noncompetitive immunoradiometric assays (Shionoria BNP ® ). Findings on ultrasonic cardiography were recorded by a SONOS 500 (Hewlett Packard, USA). The dimension of each chamber was measured in the left parasternum view using M mode, and the ejection fraction (EF) was calculated using a modified Simpson method.
Statistical Analysis
Continuous data are expressed as mean ± SD. Patient characteristics were compared using the chi-squared test and Mann -Whitney U-test. The event-free rates among the groups were calculated using the Kaplan -Meier method, and the difference among the groups was detected using the log-rank test. Statistical significance was defined as a p-value of <0.05 (one-sided) for all analyses. The Cox proportional hazards model was applied to evaluate differences in the occurrence of death or rehospitalization for CHF exacerbation among the groups after taking into account the effect of several potential confounders using SPSS software (11.0.1J for Windows, SPSS Inc, Chicago, USA).
Results

Prognostic Value of AF in CHF
As shown in Table 1 , the clinical background was similar between the SR Group and AF Group, although there were significant differences in left atrial dimension (LAD), LVEF, basal heart diseases and the administered frequency of digitalis and warfarin. Approximately one-third of each group was readmitted for CHF exacerbation during the 72-month-follow-up period. There was no significant difference in mortality (p=0.41, data not shown) or morbidity between these 2 groups (p=0.64, Fig 1) . 
Prognostic Value of Treatment Strategy for AF in CHF
As shown in Table 2 , clinical parameters were very similar between the Intervention Group and Non-Intervention Group except age, LAD, plasma BNP and basal heart diseases. There was no significant difference of mortality (p=0.37, data not shown) or morbidity (p=0.20, Fig 2) between these 2 groups.
Paroxysmal AF (PAF) as a Prognostic Indicator for CHF
The AF Group could further be classified according to the clinical forms of AF by its onset and persistence as shown in Fig 3. The Non-Intervention Group consisted of 28 patients with PAF, which spontaneously converted to SR during hospitalization and another 103 with chronic AF (CAF). When we compared the prognosis of these 2 groups, the rehospitalization rate due to CHF exacerbation was significantly higher in PAF than that in CAF (p=0.00005, Fig 4) at the statistical power of 80%, although there was no significant difference in total death. It was remarkable that 25.0% of the patients had died and a further 64.3% suffered CHF exacerbation leading to readmission during the follow-up period in the PAF group (Table 3) . When comparing the prognosis with that of the SR Group, there was no significant difference between SR and CAF while the rehospitalization rate was significantly higher in PAF than that in SR (p=0.002; Fig 4) . As shown in Table 3 , there was no significant difference in the clinical parameters with the exception of LAD, complicated frequency of myocardial ischemia and diabetes mellitus between PAF and CAF, and with the exception age between PAF and SR. In multivariate Cox analysis, the existence of PAF, but not CAF, was a significant predictor of readmission for CHF exacerbation (relative risk 2.30, p=0.004, 95% confidence interval 1.30 to 4.05) ( Table 4) .
Further analysis of PAF during the follow-up period after discharge demonstrated that 25 out of 28 cases (89%) maintained SR while they had a stable CHF status as outpatients, while PAF was again documented at hospital readmission with CHF exacerbation in 12 out of 17 cases (70%).
Discussion
Pathophysiological and Prognostic Contribution of AF to CHF
It has been emphasized that AF may compromise LV systolic function and worsen CHF through poor rate control, irregularity of the ventricular response, and loss of atrial transport, 11 as well as tachycardia-induced cardiomyopathy. 12 Conversely, some reports insisted that CHF itself could contribute to the prevalence of complicated AF through atrial remodeling or activated neurohumoral factors, including sympathetic and renin-angiotensin-aldosterone systems. 13, 14 Although it is recognized that individuals with AF are at an increased risk of death in the general population, 2 the impact of AF on CHF mortality has remained controversial despite being examined extensively. V-HeFT trials found that baseline AF was not related to overall mortality or sudden death. . 9 SOLVD trials, however, reported that AF was associated with increased mortality. 7 Studies based on CHF patients at transplant centers have reached conflicting conclusions. 15, 16 Some studies have even reported that AF has a beneficial impact on the prognosis in CHF. 10 Disparities between prior studies may be derived from several biases that reflect the focus on prevalence rather than the incidences of the disease, 7,9,16 varying duration of AF and CHF, 9, 15 and the characteristics of different referral populations. 9, 10, 15 It has been suggested that AF is only independently associated with increased mortality rates in patients with relatively preserved LV function, while the relationship is more complicated and dependent on other variables in individuals with advanced disease. 8 tality in subjects with CHF because the high mortality associated with CHF in the community might overwhelm the modest influence of preexisting AF, particularly after adjustment for other cardiovascular conditions. 17 We found in the present study population that the persistent or temporal existence of AF during the hospitalized course of CHF exacerbation was associated with morbidity. These fundamental data could lead us to focus on how to categorize and to deal with AF coincident with exacerbated CHF in further studies.
PAF as a New Predictor of Prognosis for CHF
In the present study, we found a unique impact of PAF on the prognosis of CHF as a new predictor. The PAF group categorized in our study had the peculiarity that AF was documented with CHF exacerbation and restored to SR with stabilizing CHF status. Although one report showed conflicting data that patients with PAF have a better prognosis than those with CAF in the general population, 18 its clinical value to patients with CHF has scarcely been investigated so far. To consider the causative mechanism of PAF on a worse prognostic value for CHF, we should focus on 2 paradigms: the patients' cardiac status predisposed them to the occurrence of AF; and acute hemodynamic alteration mainly derived from the cessation of regular sinus rhythm.
The predisposition of CHF to AF roughly consists of 2 pathomechanisms: irreversible and reversible processes. The former originates from organic changes, including atrial fibrosis, regional conduction abnormalities and electrophysiological changes such as a shortened atrial refractory period chronically caused by CHF. 19, 20 The latter occurs via acutely increased atrial filling pressure and atrial dilatation. 8 The significant impact of PAF should be derived from the reversible hemodynamic or cardiac background considering the pathomechanism stated above. Diastolic ventricular dysfunction causes a secondary increase in filling pressure and mediates atrial remodeling, and is associated with a 5.26-fold increase of the risk of AF development compared with normal diastolic function. 21 Complications of abnormal parameters for diastolic dysfunction, such as ischemic heart disease, hypertensive heart disease and diabetes mellitus, in the PAF group, although not significant, might contribute to the prevalence of PAF. Because it has been demonstrated that diastolic dysfunction could induce a poorer prognosis among CHF patients, similar to systolic function, 22 the diastolic property needs to be elucidated to better understand the causative mechanism. Left atrial dilatation is the only parameter that differentiates CAF from PAF. Because chronic atrial dilatation in the absence of overt CHF leads to increased vulnerability to AF through chronic regional inflammation and increased interstitial fibrosis, 23 the existence of AF in CAF may not be affected by atrial stretch stimulation with exacerbated CHF.
In contrast, the clinical characteristic of PAF is represented as an 'alteration' compared to CAF. It was demonstrated that the later development of AF, but not antecedent AF, was associated with increased mortality in CHF subjects. 17 Another report showed that the later onset of AF during the CHF course is associated with clinical and hemodynamic deterioration, and may predispose patients to systemic thromboembolism and a poorer prognosis. 24 We observed the reproducibility of PAF in conjunction with cardiac decompensation in most of the eventful PAF cases during the follow-up period. It should be reasonable to consider, therefore, that the later onset of AF, presented as PAF in the present study, can cause deteriorated hemodynamics leading to a poorer prognosis, while CAF can not.
Clinical Implications and Future Prospects: Application to New Management of AF in CHF
The choice of long-term therapy of AF in CHF is the object of intense debate. Although it is unclear whether to control the rate vs rhythm despite the subgroups analysis of AFFIRM and RACE, 3, 25 which tended to support rhythm control, the results of studies specifically designed to examine populations of patients with CHF, such as AF-CHF, 26 are needed to draw more definite conclusions. The consensus up until now, reflected in current ACC/AHA/ESC guidelines on management of AF, was that rhythm control should not be vigorously pursued in this clinical setting. 27 We did not demonstrate a beneficial outcome of the predominance of the rhythm control strategy in the present study, as indicated by the Intervention Group compared to rate control strategy in the Non-Intervention Group. It is true that the present study reached a limited conclusion for the treatment strategy for AF coincident with CHF because of its non-randomized, retrospective fashion. We could emphasize, however, that the prognosis of the PAF group was only comparable to that of the CAF group among the Non-intervention group in which no aggressive therapy for AF except ventricular rate control was undertaken. In other words, it is a reliable interpretation, even in this retrospective study, that the existence of PAF has prognostic significance. Therefore, we need to discuss which therapy should be recommended for AF in CHF patients, distinguishing PAF from CAF. Except for the emergent cases with deteriorated circulatory hemodynamics due to the additive occurrence of AF, conventional CHF management and rate control strategy without the defibrillation procedures should first of all be recommended in CHF patients with AF. When we encounter patients whose cardiac rhythms spontaneously convert from AF to SR with improving CHF status, we may propose specific management strategies. Therefore, the strategy for AF treatment can be optimized according to the pattern of AF onset and persistence because a phenotypic difference of AF could lead to a different clinical outcome in CHF. We might consider 2 ways of intervention for these PAF patients to improve the prognosis according to the presumable pathomechanisms stated above. The first possibility is the prevention of AF recurrence predominantly through the administration of preferable antiarrhythmic agents. For this purpose, amiodarone is an optimal candidate with significant potential to maintain SR, leading to lower mortality in CHF. 28 An AFFIRM study, however, demonstrated that only 35% of cases could maintain SR under the administration of amiodarone, 3 while it was reported that PAF eventually developed into its chronic form in 77.2% of patients under conventional antiarrhythmic therapy during a 14-year-follow-up. 29 Komatsu et al reported that the longterm prognosis of patients with PAF varies with the response to antiarrhythmic drug therapy. 30 The limitations of the rhythm control therapy may be recognized, considering the altered management policy of rate control, if AF has repeatedly occurred under the antiarrhythmic drug therapy. The other option is strict CHF control unless CHF status worsens, leading to the occurrence of AF. Optimal pharmacotherapy under established guidelines or a BNPguided management might approach this target. 31, 32 Further prospective studies are warranted to determine the optimal management strategy for CHF patients with AF.
Study Limitations
Some limitations of the study must be acknowledged: (1) the study was carried out inside a single center in both a retrospective and nonrandomized fashion. The acquired data might be biased because the clinical judgment depended on the clinical status of each patient. (2) It would be ideal if there was no significant difference in the clinical backgrounds between SR and AF patients. This, however, must be impossible because AF itself may lead to pathological and hemodynamic changes. (3) Although patients were carefully followed up, asymptomatic AF cannot be ruled out completely, and conversely, spontaneous termination and reinitiation of persistent AF cannot be distinguished from CAF. Despite these limitations, the present study focused for the first time on the clinical significance of PAF coincident with cardiac decompensation in CHF management. This finding raises the possibility that prophylactic therapies reduce the repeated cardiac events of exacerbated CHF to these high-risk patients. Further studies addressing the pathogenesis, prevention, and the optimal management of the AF and CHF according to the phenotype of AF seem warranted.
